← All trials
NCT04679129
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 27, 2020
- Primary completion
- Feb 14, 2021
- Completion date
- Feb 14, 2022
- First posted
- Dec 22, 2020
- Last posted
- Dec 22, 2020
- Enrollment
- 64
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Gannex Pharma Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.